Biosimilar Antibodies

Vanucizumab Biosimilar – Anti-ANGPT2, VEGFA, mAb – Research Grade, ProteoGenix, PX-TA1355

Description of Vanucizumab Biosimilar - Anti-ANGPT2, VEGFA, mAb - Research Grade General information on Anti-ANGPT2/VEGFA[Homo sapiens], (Vanucizumab) Monoclonal Antibody Vanucizumab has been investigated for the treatment of Colorectal Cancer and Advanced/Metastatic Solid Tumors.

Varlilumab Biosimilar – Anti-CD27, TNFRSF7 mAb – Research Grade, ProteoGenix, PX-TA1352

Description of Varlilumab Biosimilar - Anti-CD27, TNFRSF7 mAb - Research Grade General information on Anti-CD27/TNFRSF7[Homo sapiens] (Varlilumab) Monoclonal Antibody Varlilumab has been investigated for the treatment of Melanoma, Skin Ulcer, Burkett’s Lymphoma, Mantle cell lymphoma, and T-cell Malignancy.

Varsetatug Biosimilar – Research Grade, ProteoGenix, PX-TA2520-100

Vasigrobart Biosimilar – Research Grade, ProteoGenix, PX-TA2521-100

Vatelizumab Biosimilar – Anti-ITGA2 mAb – Research Grade, ProteoGenix, PX-TA1276

Description of Vatelizumab Biosimilar - Anti-ITGA2 mAb - Research Grade General information on Anti-ITGA2[Homo sapiens] (Vatelizumab) Monoclonal Antibody Vatelizumab has been investigated for the treatment of Ulcerative Colitis.

Vatreptacog alfa Biosimilar – Anti-FVIIa Mutant Version (FVIIaDVQ) fusion protein – Research Grade, ProteoGenix, PX-TA2274

Description of Vatreptacog alfa Biosimilar - Anti-FVIIa Mutant Version (FVIIaDVQ) fusion protein - Research Grade Vatreptacog alfa Biosimilar – Anti-FVIIa Mutant Version (FVIIaDVQ) fusion protein – Research Grade: A Promising Antibody for Therapeutic Targeting Vatreptacog alfa Biosimilar, also known as Anti-FVIIa Mutant Version (FVIIaDVQ) fusion protein, is a novel therapeutic antibody that shows great potential in treating various diseases. This biosimilar is a fusion protein that combines the binding specificity of an antibody with the activity of a clotting factor, making it a unique and powerful therapeutic agent. Structure of Vatreptacog alfa Biosimilar Vatreptacog alfa Biosimilar is a recombinant fusion protein composed of two parts – the antibody and the clotting factor. The antibody portion is derived from a monoclonal antibody that specifically binds to Factor VIIa (FVIIa), a key protein involved in the blood clotting cascade. This antibody is then fused with a mutant version of FVIIa, known as FVIIaDVQ, which has enhanced stability and prolonged activity compared to the wild-type FVIIa. The resulting fusion protein has a unique structure, with the antibody portion providing the targeting specificity and the FVIIaDVQ portion providing the clotting activity. This structure allows for precise targeting of FVIIa, while also promoting clot formation at the site of injury. Activity of Vatreptacog alfa Biosimilar The main activity of Vatreptacog alfa Biosimilar is its ability to bind to FVIIa with high affinity and inhibit its activity. FVIIa is a key protein involved in the initiation of blood clotting, and its dysregulation has been linked to various diseases, including hemophilia and thrombosis. By binding to FVIIa, Vatreptacog alfa Biosimilar effectively blocks its activity, preventing the formation of blood clots and reducing the risk of thrombotic events. In addition to its inhibitory activity, Vatreptacog alfa Biosimilar also has pro-coagulant effects due to its FVIIaDVQ component. This allows for the formation of stable blood clots at the site of injury, promoting wound healing and preventing excessive bleeding. Application of Vatreptacog alfa Biosimilar Vatreptacog alfa Biosimilar has shown promising results in preclinical studies for the treatment of hemophilia A and B, as well as other bleeding disorders. Its unique structure and dual activity make it a potential alternative to traditional clotting factor replacement therapies, which have limitations such as short half-life and the risk of developing inhibitors. Furthermore, Vatreptacog alfa Biosimilar has also shown potential in the treatment of thrombotic diseases, as it can effectively inhibit FVIIa and prevent the formation of blood clots. This makes it a promising therapeutic option for patients at high risk of thrombosis, such as those with cardiovascular diseases or undergoing surgery. Conclusion In summary, Vatreptacog alfa Biosimilar is a unique fusion protein that combines the targeting specificity of an antibody with the clotting activity of a mutant FVIIa. Its structure, activity, and potential applications make it a promising therapeutic antibody for targeting FVIIa in various diseases. Further research and clinical trials are needed to fully explore the potential of this biosimilar, but it holds great promise in improving the treatment of hemophilia, thrombosis, and other bleeding disorders.

Vedolizumab Biosimilar – Anti-ITGA4_ITGB7 mAb – Research Grade, ProteoGenix, PX-TA1212

Description of Vedolizumab Biosimilar - Anti-ITGA4_ITGB7 mAb - Research Grade General information on Anti-ITGA4_ITGB7(Homo sapiens) (Vedolizumab) Monoclonal Antibody Vedolizumab is a recombinant humanized monoclonal antibody of isotype IgG1 raised against human lymphocyte alpha 4 beta 7 integrin, a key mediator of gastrointestinal inflammation. It is used for the treatment of active ulcerative colitis and Crohn’s disease. Vedolizumab can reduce intestinal inflammation by blocking its main target alpha 4 beta 7 integrin.

Vemzatatug Biosimilar – Research Grade, ProteoGenix, PX-TA2523-100

Vibecotamab Biosimilar – Anti-CD3 epsilon, IL3RA mAb – Research Grade, ProteoGenix, PX-TA1564

Description of Vibecotamab Biosimilar - Anti-CD3 epsilon, IL3RA mAb - Research Grade Introduction Vibecotamab Biosimilar, also known as Anti-CD3 epsilon, IL3RA mAb, is a monoclonal antibody that has been developed as a biosimilar to the therapeutic antibody, Vibecotamab. This biosimilar is designed to target the CD3 epsilon subunit of the IL3RA receptor, making it a promising therapeutic option for a variety of diseases. Structure Vibecotamab Biosimilar is a fully humanized IgG1 monoclonal antibody, which means it is derived from human cells and has a structure similar to natural human antibodies. It is composed of two heavy chains and two light chains, connected by disulfide bonds. The antibody has a molecular weight of approximately 150 kDa and a half-life of around 21 days in the human body. Activity The main function of Vibecotamab Biosimilar is to bind to the CD3 epsilon subunit of the IL3RA receptor. This subunit is found on the surface of T cells, which are a type of white blood cell involved in the immune response. By binding to the CD3 epsilon subunit, Vibecotamab Biosimilar activates T cells and stimulates their proliferation, leading to an enhanced immune response. Application Vibecotamab Biosimilar has shown promising results in preclinical studies for the treatment of various diseases. Its main application is in the field of oncology, where it has been studied as a potential treatment for various types of cancer, including solid tumors and hematological malignancies. The antibody has also shown potential in the treatment of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. In oncology, Vibecotamab Biosimilar has been shown to induce tumor cell death through the activation of T cells. This mechanism of action makes it a promising option for the treatment of solid tumors, which are often difficult to target with traditional therapies. In addition, the antibody has been shown to have a synergistic effect when combined with other cancer treatments, such as chemotherapy and radiation therapy. In autoimmune diseases, Vibecotamab Biosimilar has been shown to modulate the immune response, leading to a reduction in inflammation and disease symptoms. This makes it a potential treatment option for patients who do not respond well to traditional therapies or experience significant side effects. Research Grade Vibecotamab Biosimilar is currently in the research grade stage, which means it is still undergoing preclinical and clinical studies to determine its safety and efficacy in humans. These studies are necessary before the antibody can be approved for use in patients. Conclusion In summary, Vibecotamab Biosimilar is a promising monoclonal antibody that targets the CD3 epsilon subunit of the IL3RA receptor. Its structure, activity, and potential applications make it a promising therapeutic option for a variety of diseases, particularly in the fields of oncology and autoimmune diseases. With continued research and development, this biosimilar has the potential to improve patient outcomes and contribute to the advancement of medical treatments.

Vibostolimab Biosimilar – Anti-TIGIT, VSIG9, VSTM3 mAb – Research Grade, ProteoGenix, PX-TA1610

Description of Vibostolimab Biosimilar - Anti-TIGIT, VSIG9, VSTM3 mAb - Research Grade The Structure of Vibostolimab Biosimilar – Anti-TIGIT, VSIG9, VSTM3 mAb Vibostolimab Biosimilar, also known as Anti-TIGIT, VSIG9, VSTM3 mAb, is a monoclonal antibody (mAb) that has been developed as a potential therapeutic agent for various diseases. This biosimilar is a type of antibody that specifically targets and binds to T-cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT), VSIG9, and VSTM3 proteins. These proteins are known to play a crucial role in regulating immune responses, making them attractive therapeutic targets for various diseases. The structure of Vibostolimab Biosimilar is based on the structure of the original antibody, which was first discovered and characterized by scientists. It is a fully humanized IgG1 antibody, meaning that it is derived from human cells and has a similar structure to the antibodies naturally produced in the human body. This makes it less likely to cause an immune response when administered to patients. The antibody has a Y-shaped structure, with two identical heavy chains and two identical light chains. Each chain is made up of constant and variable regions. The constant regions are responsible for the effector functions of the antibody, while the variable regions are responsible for binding to the specific target proteins. The Activity of Vibostolimab Biosimilar Vibostolimab Biosimilar is a potent inhibitor of TIGIT, VSIG9, and VSTM3 proteins. These proteins are expressed on the surface of various immune cells, including T cells, natural killer (NK) cells, and dendritic cells. When TIGIT, VSIG9, and VSTM3 proteins bind to their ligands, they inhibit immune cell activation, leading to suppression of immune responses. By binding to these proteins, Vibostolimab Biosimilar blocks their interaction with their ligands, thereby preventing the inhibition of immune cell activation. This results in the enhancement of immune responses, making it a potential therapeutic agent for diseases where immune responses are suppressed, such as cancer and autoimmune diseases. In addition to its inhibitory activity, Vibostolimab Biosimilar also has the ability to induce antibody-dependent cell-mediated cytotoxicity (ADCC). This means that it can trigger immune cells, such as NK cells, to attack and kill target cells, such as cancer cells, that have been marked by the antibody. This dual mechanism of action makes Vibostolimab Biosimilar a promising candidate for cancer immunotherapy. The Application of Vibostolimab Biosimilar Vibostolimab Biosimilar is currently being evaluated in clinical trials for the treatment of various diseases, including solid tumors, hematological malignancies, and autoimmune diseases. In preclinical studies, it has shown promising results in inhibiting tumor growth and enhancing immune responses against cancer cells. In addition to its potential as a cancer therapy, Vibostolimab Biosimilar is also being investigated for its use in autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis. By enhancing immune responses, it may help to regulate the overactive immune system and reduce inflammation in these diseases. Furthermore, the biosimilar is being studied for its potential use in combination with other therapies, such as immune checkpoint inhibitors, to further enhance immune responses and improve treatment outcomes. Conclusion In summary, Vibostolimab Biosimilar – Anti-TIGIT, VSIG9, VSTM3 mAb – Research Grade is a promising therapeutic agent with a unique structure and dual mechanism of action. Its ability to inhibit TIGIT, VSIG9, and VSTM3 proteins and induce ADCC makes it a potential treatment option for various diseases, including cancer and autoimmune diseases. Further clinical trials will help to determine its safety and efficacy, and if successful, it could become a valuable addition to the arsenal of therapies available for these diseases.